

DAFTAR PUSTAKA

Gladson, C.L., Prayson, R.A. and Liu, W.M. (2010) 'The pathobiology of glioma tumors', *Annual Review of Pathology: Mechanisms of Disease*, 5(1), pp. 33–50. doi:10.1146/annurev-pathol-121808-102109.

Arcella, A. et al. (2020) 'Dissecting molecular features of gliomas: Genetic loci and validated biomarkers', *International Journal of Molecular Sciences*, 21(2), p. 685. doi:10.3390/ijms21020685.

Gemini, L. et al. (2023) 'Vasari scoring system in discerning between different degrees of glioma and IDH status prediction: A possible machine learning application?', *Journal of Imaging*, 9(4), p. 75. doi:10.3390/jimaging9040075.

Gladson, C.L., Prayson, R.A. and Liu, W.M. (2010) 'The pathobiology of glioma tumors', *Annual Review of Pathology: Mechanisms of Disease*, 5(1), pp. 33–50. doi:10.1146/annurev-pathol-121808-102109.

Herholz, K. et al. (2012) 'Brain tumors', *Seminars in Nuclear Medicine*, 42(6), pp. 356–370. doi:10.1053/j.semnuclmed.2012.06.001.

Jeuken, J.W., Wesseling, P. and Reifenberger, G. (2010) 'Molecular diagnostics of gliomas: State of the art', *Acta Neuropathologica*, 120(5), pp. 567–584. doi:10.1007/s00401-010-0736-4.

Masui, K., Mischel, P.S. and Reifenberger, G. (2016) 'Molecular classification of gliomas', *Handbook of Clinical Neurology*, pp. 97–120. doi:10.1016/b978-0-12-802997-8.00006-2.

Ostrom, Q.T. et al. (2014) 'Epidemiology of gliomas', *Cancer Treatment and Research*, pp. 1–14. doi:10.1007/978-3-319-12048-5_1.

Schwartzbaum, J.A. et al. (2006) 'Epidemiology and molecular pathology of glioma', *Nature Clinical Practice Neurology*, 2(9), pp. 494–503. doi:10.1038/ncpneuro0289.

Singh, G. et al. (2021) 'Radiomics and radiogenomics in gliomas: A contemporary update', *British Journal of Cancer*, 125(5), pp. 641–657. doi:10.1038/s41416-021-01387-w.

Theresia, E. et al. (2020) 'Association between Ki-67 labeling index and histopathological grading of glioma in Indonesian population', *Asian Pacific Journal of Cancer Prevention*, 21(4), pp. 1063–1068. doi:10.31557/apjcp.2020.21.4.1063.

Bodalal, Z. et al. (2019) 'Radiogenomics: Bridging Imaging and Genomics', *Abdominal Radiology*, 44(6), pp. 1960–1984. doi:10.1007/s00261-019-02028-w.

Cao, M. et al. (2021) 'Qualitative and quantitative MRI analysis in IDH1 genotype prediction of lower-grade gliomas: A machine learning approach', *BioMed Research International*, 2021, pp. 1–10. doi:10.1155/2021/1235314.

Gore, S. et al. (2021) 'A review of Radiomics and deep predictive modeling in glioma characterization', *Academic Radiology*, 28(11), pp. 1599–1621. doi:10.1016/j.acra.2020.06.016.

Omuro, A. (2013) 'Glioblastoma and other malignant gliomas', *JAMA*, 310(17), p. 1842. doi:10.1001/jama.2013.280319.

Singh, G. et al. (2021) 'Radiomics and radiogenomics in gliomas: A contemporary update', *British Journal of Cancer*, 125(5), pp. 641–657. doi:10.1038/s41416-021-01387-w.

Avellaneda Matteo, D. et al. (2017) 'Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency', *Journal of Biological Chemistry*, 292(19), pp. 7971–7983. doi:10.1074/jbc.m117.776179.

Gusyatiner, O. and Hegi, M.E. (2018) 'Glioma epigenetics: From subclassification to novel treatment options', *Seminars in Cancer Biology*, 51, pp. 50–58. doi:10.1016/j.semcancer.2017.11.010.

Weller, M. et al. (2017) 'European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas', *The Lancet Oncology*, 18(6). doi:10.1016/s1470-2045(17)30194-8.

Yang, K. et al. (2022) 'Glioma targeted therapy: Insight into future of molecular approaches', *Molecular Cancer*, 21(1). doi:10.1186/s12943-022-01513-z.

Bell, D. and Jones, J. (2009) 'MRI', *Radiopaedia.org* [Preprint]. doi:10.53347/rid-6317.

Chavhan, G.B. (2016) 'Appropriate selection of MRI sequences for common scenarios in clinical practice', *Pediatric Radiology*, 46(6), pp. 740–747. doi:10.1007/s00247-016-3556-4.

Pai, A. et al. (2023) *Magnetic Resonance Imaging Physics - StatPearls - NCBI Bookshelf*. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK564320/> (Accessed: 07 June 2023).

Ridgway, J.P. (2010) 'Cardiovascular magnetic resonance physics for clinicians: Part I', *Journal of Cardiovascular Magnetic Resonance*, 12(1). doi:10.1186/1532-429x-12-71.

Biswas, A. et al. (2022) 'Features of visually accesable Rembrandt Images: Interrater Reliability in pediatric brain tumors', *American Journal of Neuroradiology*, 43(2), pp. 304–308. doi:10.3174/ajnr.a7399.

Gaillard, F. (2016) 'Vasari MRI feature set', *Radiopaedia.org* [Preprint]. doi:10.53347/rid-45816.

Grover, V.P.B. et al. (2015) 'Magnetic Resonance Imaging: Principles and techniques: Lessons for clinicians', *Journal of Clinical and Experimental Hepatology*, 5(3), pp. 246–255. doi:10.1016/j.jceh.2015.08.001.

Louis, D.N. (2006) 'Molecular pathology of malignant gliomas', *Annual Review of Pathology: Mechanisms of Disease*, 1(1), pp. 97–117. doi:10.1146/annurev.pathol.1.110304.100043.

Singh, G. et al. (2021) 'Radiomics and radiogenomics in gliomas: A contemporary update', *British Journal of Cancer*, 125(5), pp. 641–657. doi:10.1038/s41416-021-01387-w.

You, W. et al. (2023) 'The combination of radiomics features and Vasari standard to predict glioma grade', *Frontiers in Oncology*, 13. doi:10.3389/fonc.2023.1083216.

Yu, J. et al. (2016) 'Potential utility of visually accesable Rembrandt images assessment in brain astrocytoma grading', *Journal of Computer Assisted Tomography*, 40(2), pp. 301–306. doi:10.1097/rct.0000000000000352.

'What is an MRI scan and what can it do?' (2011) *Drug and Therapeutics Bulletin*, 49(12), pp. 141–144. doi:10.1136/dtb.2011.02.0073.

Brown TA. *Genomes*. 2nd edition. Oxford: Wiley-Liss; 2002. Chapter 14, Mutation, Repair and Recombination. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK21114/>

Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy. *Nat Rev Clin Oncol*. 2021 Oct;18(10):645-661. doi: 10.1038/s41571-021-00521-0. Epub 2021 Jun 15. PMID: 34131315.

Lattanzio, L. et al. (2015) 'MGMT promoter methylation and glioblastoma: A comparison of analytical methods and of tumor specimens', *The International Journal of Biological Markers*, 30(2), pp. 208–216. doi:10.5301/jbm.5000126.

Nassiri, F., Zadeh, G. and Aldape, K. (2017) 'IDH mutation testing in gliomas—where do we draw the line?', *Neuro-Oncology*, 19(12), pp. 1568–1569. doi:10.1093/neuonc/nox164.

Røge, R. et al. (2020) 'Ki-67 proliferation index in breast cancer as a function of assessment method: A NORDIQC experience', *Applied Immunohistochemistry & Molecular Morphology*, 29(2), pp. 99–104. doi:10.1097/pai.0000000000000846.

Wirsching, H.-G. et al. (2018) 'Basics of diagnosis and therapy of gliomas', *Der Nervenarzt*, 89(6), pp. 692–698. doi:10.1007/s00115-018-0519-z.

Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee ShU. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. *Asian Pac J Cancer Prev*. 2017 Jan 1;18(1):3-9. doi: 10.22034/APJCP.2017.18.1.3. PMID: 28239999; PMCID: PMC5563115.

Pellerino, A., Caccese, M., Padovan, M. et al. Epidemiology, risk factors, and prognostic factors of gliomas. *Clin Transl Imaging* 10, 467–475 (2022).

Bell, D. and Di Muzio, B. (2015) '1P19Q codeletion', *Radiopaedia.org* [Preprint]. doi:10.53347/rid-39164.

Ellingson, B.M. (2014) 'Radiogenomics and imaging phenotypes in glioblastoma: Novel observations and correlation with molecular characteristics', *Current Neurology and Neuroscience Reports*, 15(1). doi:10.1007/s11910-014-0506-0.

Ijzerman-Korevaar, M. et al. (2018) 'Prevalence of symptoms in glioma patients throughout the disease trajectory: A systematic review', *Journal of Neuro-Oncology*, 140(3), pp. 485–496. doi:10.1007/s11060-018-03015-9.

Kao, H.-W. et al. (2013) 'Advanced MR imaging of gliomas: An update', *BioMed Research International*, 2013, pp. 1–14. doi:10.1155/2013/970586.

Louis, D.N. et al. (2021) 'The 2021 WHO classification of tumors of the central nervous system: A summary', *Neuro-Oncology*, 23(8), pp. 1231–1251. doi:10.1093/neuonc/noab106.

Mandal, A.S., Brem, S. and Suckling, J. (2023) 'Brain Network Mapping and glioma pathophysiology', *Brain Communications*, 5(2). doi:10.1093/braincomms/fcad040.

Mizoguchi, M. et al. (2012) 'Molecular characteristics of glioblastoma with 1P/19Q co-deletion', *Brain Tumor Pathology*, 29(3), pp. 148–153. doi:10.1007/s10014-012-0107-z.

Norden, A.D. and Wen, P.Y. (2006) 'Glioma therapy in adults', *The Neurologist*, 12(6), pp. 279–292. doi:10.1097/01.nrl.0000250928.26044.47.

Omuro, A. (2013) 'Glioblastoma and other malignant gliomas', *JAMA*, 310(17), p. 1842. doi:10.1001/jama.2013.280319.

Politi, L.S. and Levi, R. (2022) 'Editorial comment: Radiogenomics of glioblastoma: Shifting the focus from tumor cells to immune microenvironment', *European Radiology*, 33(1), pp. 207–208. doi:10.1007/s00330-022-09195-3.

Haydar, N. et al. (2022) 'Role of magnetic resonance imaging (MRI) in grading gliomas comparable with pathology: A cross-sectional study from Syria', *Annals of Medicine & Surgery*, 82. doi:10.1016/j.amsu.2022.104679.

Amdouni, E. and Gibaud, B. (2018) 'Semantic representation of neuroimaging observations: Proof of concept based on the Vasari terminology', *Proceedings of the 10th International Joint Conference on Knowledge Discovery, Knowledge Engineering and Knowledge Management [Preprint]*. doi:10.5220/0006931100630074.

Gemini, L. et al. (2023) Vasari scoring system in discerning between different degrees of glioma and IDH status prediction: A possible machine learning application?, *Journal of imaging*. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143099/> (Accessed: 30 July 2024).

Jovanović, N. et al. (2022) 'The significance of MGMT promoter methylation status in diffuse glioma', *International Journal of Molecular Sciences*, 23(21), p. 13034. doi:10.3390/ijms232113034.

Park, Y.W. et al. (2018) Prediction of idh1-mutation and 1P/19Q-codeletion status using preoperative MR imaging phenotypes in lower grade gliomas, *AJNR. American journal of neuroradiology*. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410710/> (Accessed: 30 July 2024).

Xing, Z. et al. (2017) 'Noninvasive assessment of idh mutational status in World Health Organization Grade II and III astrocytomas using DWI and DSC-PWI combined with conventional MR imaging', *American Journal of Neuroradiology*, 38(6), pp. 1138–1144. doi:10.3174/ajnr.a5171.

Ostrom, Q.T., Cote, D.J., Ascha, M., Kruchko, C. and Barnholtz-Sloan, J.S. (2018). Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014. *JAMA oncology*, [online] 4(9), pp.1254–1262. doi:<https://doi.org/10.1001/jamaoncol.2018.1789>.

Wang, G.-M., Cioffi, G., Patil, N., Waite, K.A., Lanese, R., Ostrom, Q., Kruchko, C., Berens, M.E., Connor, J.R., Lathia, J.D., Rubin, J.B. and Barnholtz-Sloan, J.S. (2021). Importance of the intersection of age and sex to understand variation in incidence and

doi:<https://doi.org/10.1093/neuonc/noab199>.

Das, J.M. (2023). High-Grade Gliomas. In: *Neuro-Oncology Explained Through Multiple Choice Questions*. Springer, Cham. https://doi.org/10.1007/978-3-031-13253-7_15

Alzial, G., Renoult, O., Paris, F., Gratas, C., Clavreul, A. and Pecqueur, C. (2021). Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma. *Oncogene*, [online] 41(5), pp.613–621. doi:<https://doi.org/10.1038/s41388-021-02056-1>.

Tini, P., Mariya Yavoroska, Maria Antonietta Mazzei, Miracco, C., Pirtoli, L., Tomaciello, M., Marampon, F. and Minniti, G. (2023). Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status. *Journal of Neuro-oncology*, 163(2), pp.339–344. doi:<https://doi.org/10.1007/s11060-023-04342-2>.

Mousa, M.I. et al. (2023) ‘Mapping high-grade glioma response to chemoradiotherapy: Insights from fractional anisotropy and mean diffusivity’, *Journal of Radiation Research and Applied Sciences*, 16(4), p. 100706. doi:10.1016/j.jrras.2023.100706.

Najafi, S., Esmaeili, S., Hossein Zhaleh and Rahmati, Y. (2022). The role of IDH1 mutation on gene expression in glioblastoma. *Informatics in Medicine Unlocked*, 28, pp.100812–100812. doi:<https://doi.org/10.1016/j.imu.2021.100812>.

Han, Q., Liang, H., Cheng, P., Yang, H. and Zhao, P. (2020). Gross Total vs. Subtotal Resection on Survival Outcomes in Elderly Patients With High-Grade Glioma: A Systematic Review and Meta-Analysis. *Frontiers in Oncology*, 10. doi:<https://doi.org/10.3389/fonc.2020.00151>.

Wijethilake, N., Islam, M. and Ren, H. (2020) ‘Radiogenomics model for overall survival prediction of glioblastoma’, *Medical & Biological Engineering & Computing*, 58(8), pp. 1767–1777. doi:10.1007/s11517-020-02179-9.

Parastuta, K.Y., Sriwidayani, N.P., Ekawati, N.P. and Saputra, H. (2020). GAMBARAN KLINIKOPATOLOGI TUMOR GLIA TAHUN 2014 - 2018 DI RSUP SANGLAH DENPASAR. *JURNAL MEDIKA UDAYANA*, Vol. 7(9).